Evidence map›Paper›PMID 39555815›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Nanoengineering of Phosphate/Phosphonate Drugs via Competitive Replacement with Metal-Phenolic Networks to Overcome Breast Tumor with Lung and Bone Metastasis.

Wanrui Shi, Dashuai Liu, Wenjie Feng, Yang Chen, Yonggang Wang, Zhihong Nie, Yi Liu, Hao Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wanrui ShiJoint Laboratory of Opto-Functional Theranostics in Medicine and Chemistry, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, 130021, P. R. China.
Dashuai LiuState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, P. R. China.
Wenjie FengJoint Laboratory of Opto-Functional Theranostics in Medicine and Chemistry, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, 130021, P. R. China.
Yang ChenState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, P. R. China.
Yonggang WangDepartment of Cardiovascular Centre, The First Hospital of Jilin University, Changchun, 130012, P. R. China.
Zhihong NieState Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai, 200438, P. R. China.
Yi LiuJoint Laboratory of Opto-Functional Theranostics in Medicine and Chemistry, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, 130021, P. R. China.
Hao ZhangJoint Laboratory of Opto-Functional Theranostics in Medicine and Chemistry, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, 130021, P. R. China.ORCID 0000-0002-2373-1100

Funding

Postdoctoral Fellowship Program of CPSF GZC20230949Science and Technology Development Program of Changchun City 23***13Science and Technology Development Program of Jilin Province ***202302001Special Project from MOST of China
6 · The paper itself

Abstract

Phosphate and phosphonate drugs are vital in building organisms, regulating physiological processes, and exhibiting diverse biological activities, including antiviral, antibacterial, antineoplastic, and enzyme-inhibitory effects. However, their therapeutic potential is limited by the lack of advanced nanoengineering technologies. Herein, a competitive coordination strategy for nanoengineering phosphate/phosphonate drugs is introduced. By leveraging the difference in coordination capabilities between polyphenols and phosphates/phosphonates with metal ions, various phosphate/phosphonate-based nanodrugs using metal-phenolic networks (MPNs) as templates and phosphate/phosphonate drugs as competitive agents are constructed. The dynamic nature of these coordination bonds imparts stimuli-responsiveness to the nanodrugs, allowing for targeted release and therapy. As a proof of concept, Fe

Indexed as

Bone NeoplasmsBreast NeoplasmsLung NeoplasmsPhosphatesAnimalsAntineoplastic AgentsCell Line, TumorFemaleHumansMiceNanotechnologyAntineoplastic AgentsPhosphatescompetitive coordinationmetal‐phenolic networksnanoengineeringphosphates and phosphonatesself‐assembly

Identifiers

PMID39555815
PMCPMC11727113

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.